Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cymabay Therapeutics Inc. (NASDAQ: CBAY).

Full DD Report for CBAY

You must become a subscriber to view this report.


Recent News from (NASDAQ: CBAY)

Novartis In Liver Diseases NASH And PBC: A Look At The Bright Side
There can be no greater gift than that of giving one’s time and energy to help others without expecting anything in return. —Nelson Mandela Novartis AG (NVS) is a Swiss (Basel, Switzerland) multibillion biopharmaceutical company with a market cap of $178B and a broad the...
Source: SeekingAlpha
Date: May, 17 2018 14:35
Wired News - CymaBay Therapeutics Starts Phase-2b Clinical Trials of Seladelpar for Treatment of Patients with Non-Alcoholic Steatohepatitis
Stock Monitor: Cerecor Post Earnings Reporting LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want access to our free research report on CymaBay Therapeutics, Inc. (NASDAQ: CBAY ), all you need to do is sign up now by clicking the following link www.active-investors.com/registration...
Source: ACCESSWIRE IA
Date: May, 10 2018 07:40
CymaBay Therapeutics' (CBAY) CEO Sujal Shah on Q1 2018 Results - Earnings Call Transcript
CymaBay Therapeutics (CBAY) Q1 2018 Earnings Conference Call May 8, 2018 04:30 PM ET Executives Dan Menold - Vice President, Finance Sujal Shah - Chief Executive Officer Pol Boudes - Chief Medical Officer Chuck McWherter - Chief Scientific Officer Analysts Jason Kolbert -...
Source: SeekingAlpha
Date: May, 08 2018 22:43
CymaBay Reports First Quarter 2018 Financial Results and Provides Corporate Update
Conference call and webcast today at 4:30p.m. ET NEWARK, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY) a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced ...
Source: GlobeNewswire
Date: May, 08 2018 16:01
CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic Steatohepatitis
NEWARK, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it began screening of patients for a phase 2b...
Source: GlobeNewswire
Date: May, 08 2018 08:00
Cirius Therapeutics completes enrollment in mid-stage study of lead candidate in NASH
Privately held Cirius Therapeutics announces that it has reached the enrollment target in a Phase 2b clinical trial, EMMINENCE , assessing lead candidate MSDC-0602K in patients with NASH and liver fibrosis. More news on: Conatus Pharmaceuticals, Galectin Therapeutics, Inc., Navidea Bi...
Source: SeekingAlpha
Date: May, 02 2018 10:47
CymaBay to Report First Quarter 2018 Financial Results on Tuesday, May 8
NEWARK, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio...
Source: GlobeNewswire
Date: May, 01 2018 08:00
CymaBay Makes Progress With Seladelpar
CymaBay (CBAY) last week reported fresh data with its lead product candidate seladelpar in patients with primary biliary cholangitis ((PBC)). The data was promising on both the fronts, safety and efficacy. With the new data, the company now remains on track to advance seladelpar into phase 3...
Source: SeekingAlpha
Date: April, 30 2018 14:22
Report: Developing Opportunities within CymaBay Therapeutics, IAC/InterActiveCorp, Axcelis Technologies, La Quinta, Hornbeck Offshore Services, and Sprouts Farmers Market - Future Expectations, Projections Moving into 2018
NEW YORK, April 20, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of CymaBay Therapeutics Inc. (NASDAQ:CBAY), IAC/InterActiveCorp (NASDAQ:IAC...
Source: GlobeNewswire
Date: April, 20 2018 08:25
Biotechs, Whipsawed By Volatility, Still Remain Well-Positioned
Biotech Pulse When the market experiences rain, biotechs experience a thunderstorm. That's how volatility relates to biotechnology - one of the most promising and nerve-wracking industries in the stock market. As the market succumbed last week to the drumbeat of a tariff war, volatility sp...
Source: SeekingAlpha
Date: April, 13 2018 09:17

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-2012.1711.9912.3511.95262,336
2018-08-1712.1812.27512.3512.01232,788
2018-08-1612.0312.2412.3311.9054366,148
2018-08-1512.3411.9112.4511.77259,363
2018-08-1412.1612.4112.6412.01357,052

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-2077,423111,74769.2842Short
2018-08-1742,00561,24468.5863Short
2018-08-1662,276118,52552.5425Short
2018-08-1536,79075,82748.5183Short
2018-08-1460,401111,87553.9897Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CBAY.


About Cymabay Therapeutics Inc. (NASDAQ: CBAY)

Logo for Cymabay Therapeutics Inc. (NASDAQ: CBAY)

Not available

 

Contact Information

 

 

Current Management

  • Sujal Shah / CFO

Current Share Structure

  • Market Cap: $682,715,936 - 05/14/2018
  • Authorized: 100,000,000 - 09/30/2013
  • Issue and Outstanding: 58,501,794 - 02/28/2018

 


Recent Filings from (NASDAQ: CBAY)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 20 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 20 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 20 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 15 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 15 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: February, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 13 2018

 

 


Daily Technical Chart for (NASDAQ: CBAY)

Daily Technical Chart for (NASDAQ: CBAY)


Stay tuned for daily updates and more on (NASDAQ: CBAY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CBAY)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CBAY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CBAY and does not buy, sell, or trade any shares of CBAY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/